Characterizing the diverse mutational pathways associated with R5-tropic Maraviroc resistance HIV-1 that uses the drug-bound CCR5 coreceptor

Xiaowei Jiang, Felix Feyertag, Conor J Meehan, Grace P McCormack, Simon A Travers, Charles Craig, Mike Westby, Marilyn Lewis, David L Robertson

Research output: Contribution to journalA1: Web of Science-article

31 Downloads (Pure)

Abstract

Entry inhibitors represent a potent class of antiretroviral drugs that target a host cell protein, CCR5, an HIV-1 entry coreceptor, and not viral protein. Lack of sensitivity can occur due to preexisting virus that uses the CXCR4 coreceptor, while true resistance occurs through viral adaptation to use a drug-bound CCR5 coreceptor. To understand this R5 resistance pathway, we analyzed >500 envelope protein sequences and phenotypes from viruses of 20 patients from the clinical trials MOTIVATE 1 and 2, in which treatment-experienced patients received maraviroc plus optimized background therapy. The resistant viral population was phylogenetically distinct and associated with a genetic bottleneck in each patient, consistent with de novo emergence of resistance. Recombination analysis showed that the C2-V3-C3 region tends to genotypically correspond to the recombinant's phenotype, indicating its primary importance in conferring resistance. Between patients, there was a notable lack of commonality in the specific sites conferring resistance, confirming the unusual nature of R5-tropic resistance. We used coevolutionary and positive-selection analyses to characterize the genotypic determinants of resistance and found that (i) there are complicated covariation networks, indicating frequent coevolutionary/compensatory changes in the context of protein structure; (ii) covarying sites under positive selection are enriched in resistant viruses; (iii) CD4 binding sites form part of a unique covariation network independent of the V3 loop; and (iv) the covariation network formed between the V3 loop and other regions of gp120 and gp41 intersects sites involved in glycosylation and protein secretion. These results demonstrate that while envelope sequence mutations are the key to conferring maraviroc resistance, the specific changes involved are context dependent and thus inherently unpredictable.

Original languageEnglish
JournalJournal of Virology
Volume89
Issue number22
Pages (from-to)11457-11472
Number of pages16
ISSN0022-538X
DOIs
Publication statusPublished - 2015

Fingerprint

Dive into the research topics of 'Characterizing the diverse mutational pathways associated with R5-tropic Maraviroc resistance HIV-1 that uses the drug-bound CCR5 coreceptor'. Together they form a unique fingerprint.

Cite this